Title 42 — The Public Health and WelfareRelease 119-83
§1395w–114 Premium and cost-sharing subsidies for low-income individuals
Title 42 › Chapter CHAPTER 7— - SOCIAL SECURITY › Subchapter SUBCHAPTER XVIII— - HEALTH INSURANCE FOR AGED AND DISABLED › Part Part D— - Voluntary Prescription Drug Benefit Program › Subpart subpart 2— - prescription drug plans; pdp sponsors; financing › § 1395w–114
Summary
Helps people with very low income and small savings pay for Medicare prescription drug coverage. If a person has income at or below 135 percent of the poverty line (or 150 percent for plan years starting on or after January 1, 2024) and meets the resource limits, the law pays their premium up to the low‑income benchmark amount (or more if specified), lowers or removes the deductible (to $0 for the lowest group), and cuts drug cost sharing or coinsurance. People who get both full Medicaid and Medicare (full‑benefit dual eligibles) often pay no coinsurance if they live in an institution; other dual eligibles with income at or below 100 percent of poverty have small fixed copays for drugs: before 2028 generic or preferred multiple‑source drugs cost $1 (or less) and other drugs $3 (or less), and beginning in 2028 generic drugs are $0 with other amounts adjusted each year by the Consumer Price Index. For plan years before 2024, people with income between 135 percent and 150 percent get a sliding premium help (100 percent down to 0), a $50 deductible, and coinsurance reduced from 25 percent to 15 percent. For years before 2024, cost sharing for covered insulin products is eliminated, and for 2023 and later insulin copays may not exceed the copay under the person’s plan. Adult vaccines recommended by the Advisory Committee on Immunization Practices have no deductible and no cost sharing starting January 1, 2023. A “subsidy eligible individual” means a person eligible for Part D who is enrolled in a drug plan, has income under 150 percent of poverty, and meets resource limits. A “LI NET eligible individual” means a person who meets the income and resource rules but has not yet started plan coverage. States or the Social Security Administration decide who qualifies and how long the decision lasts (usually up to 1 year), and they handle redeterminations and appeals. Resource limits use rules tied to the Supplemental Security Income program for some years, and for plan years beginning on or after January 1, 2024 the dollar test starts at $10,000 ($20,000 combined with a spouse) for 2006 and rises each year with the Consumer Price Index. Plans can waive very small monthly premiums, and the government reimburses plans for the subsidies while keeping personal data confidential. Starting January 1, 2024, the Secretary must run a transitional coverage program so LI NET eligible people can get covered Part D drugs at the pharmacy immediately, and certain low‑income people can get retroactive reimbursement for drugs bought up to 36 months before they enroll.
Full Legal Text
Title 42, §1395w–114
The Public Health and Welfare — Source: USLM XML via OLRC
(a)(1)In the case of a subsidy eligible individual (as defined in paragraph (3)) who is determined to have income that is below 135 percent (or, with respect to a plan year beginning on or after January 1, 2024, 150 percent) of the poverty line applicable to a family of the size involved and who meets the resources requirement described in paragraph (3)(D) (or, with respect to a plan year beginning on or after January 1, 2024, paragraph (3)(E)) or who is covered under this paragraph under paragraph (3)(B)(i), the individual is entitled under this section to the following:
(A)An income-related premium subsidy equal to 100 percent of the amount described in subsection (b)(1), but not to exceed the premium amount specified in subsection (b)(2)(B).
(B)A reduction in the annual deductible applicable under section 1395w–102(b)(1) of this title to $0.
(C)For a year preceding 2025, the continuation of coverage from the initial coverage limit (under paragraph (3) of section 1395w–102(b) of this title) for expenditures incurred through the total amount of expenditures at which benefits are available under paragraph (4) of such section, subject to the reduced cost-sharing described in subparagraph (D).
(D)(i)In the case of an individual who is a full-benefit dual eligible individual and who is an institutionalized individual or couple (as defined in section 1396a(q)(1)(B) of this title) or, effective on a date specified by the Secretary (but in no case earlier than January 1, 2012), who would be such an institutionalized individual or couple, if the full-benefit dual eligible individual were not receiving services under a home and community-based waiver authorized for a State under section 1315 of this title or subsection (c) or (d) of section 1396n of this title or under a State plan amendment under subsection (i) of such section or services provided through enrollment in a medicaid managed care organization with a contract under section 1396b(m) of this title or under section 1396u–2 of this title, the elimination of any beneficiary coinsurance described in section 1395w–102(b)(2) of this title (for all amounts through the total amount of expenditures at which benefits are available under section 1395w–102(b)(4) of this title).
(ii)Subject to paragraph (6), in the case of an individual not described in clause (i) who is a full-benefit dual eligible individual and whose income does not exceed 100 percent of the poverty line applicable to a family of the size involved, the substitution for the beneficiary coinsurance described in section 1395w–102(b)(2) of this title (for all amounts through the total amount of expenditures at which benefits are available under section 1395w–102(b)(4) of this title) of a copayment amount that does not exceed—
(I)for a plan year before 2028—
(aa)for a generic drug or a preferred drug that is a multiple source drug (as defined in section 1396r–8(k)(7)(A)(i) of this title), $1 or, if less, the copayment amount applicable to an individual under clause (iii); and
(bb)for any other drug, $3 or, if less, the copayment amount applicable to an individual under clause (iii); and
(II)for plan year 2028 and each subsequent plan year—
(aa)for a generic drug, $0;
(bb)for a preferred drug that is a multiple source drug (as defined in section 1396r–8(k)(7)(A)(i) of this title), the dollar amount applied under this clause for such a drug for the preceding plan year, increased by the annual percentage increase in the consumer price index (all items; U.S. city average) as of September of such preceding year, or, if less, the copayment amount applicable to an individual under clause (iii); and
(cc)for a drug not described in either item (aa) or (bb), the dollar amount applied under this clause for such a drug for the preceding plan year, increased in the manner specified in item (bb), or, if less, the copayment amount applicable to an individual under clause (iii).
(iii)Subject to paragraph (6), in the case of an individual not described in clause (i) or (ii), the substitution for the beneficiary coinsurance described in section 1395w–102(b)(2) of this title (for all amounts through the total amount of expenditures at which benefits are available under section 1395w–102(b)(4) of this title) of a copayment amount that does not exceed the copayment amount specified under section 1395w–102(b)(4)(A)(i)(I)(aa) of this title for the drug and year involved. For plan year 2023 and subsequent plan years, the copayment amount applicable under the preceding sentence to a month’s supply of a covered insulin product (as defined in section 1395w–102(b)(9)(C) of this title) dispensed to the individual may not exceed the applicable copayment amount for the product under the prescription drug plan or MA–PD plan in which the individual is enrolled.
(E)For a year preceding 2024, the elimination of any cost-sharing imposed under section 1395w–102(b)(4)(A) of this title or under section 1395w–102(b)(9) of this title in the case of a covered insulin product (as defined in subparagraph (C) of such section).
(2)With respect to a plan year beginning before January 1, 2024, in the case of a subsidy eligible individual who is not described in paragraph (1), the individual is entitled under this section to the following:
(A)An income-related premium subsidy determined on a linear sliding scale ranging from 100 percent of the amount described in paragraph (1)(A) for individuals with incomes at or below 135 percent of such level to 0 percent of such amount for individuals with incomes at 150 percent of such level.
(B)Subject to paragraphs (8) and (9) of section 1395w–102(b) of this title, a reduction in the annual deductible applicable under section 1395w–102(b)(1) of this title to $50.
(C)The continuation of coverage from the initial coverage limit (under paragraph (3) of section 1395w–102(b) of this title) for expenditures incurred through the total amount of expenditures at which benefits are available under paragraph (4) of such section, subject to the reduced coinsurance described in subparagraph (D).
(D)Subject to paragraph (6), the substitution for the beneficiary coinsurance described in section 1395w–102(b)(2) of this title (for all amounts above the deductible under subparagraph (B) through the total amount of expenditures at which benefits are available under section 1395w–102(b)(4) of this title) of coinsurance of “15 percent” instead of coinsurance of “25 percent” in section 1395w–102(b)(2) of this title. For plan year 2023, the amount of the coinsurance applicable under the preceding sentence to a month’s supply of a covered insulin product (as defined in section 1395w–102(b)(9)(C) of this title) dispensed to the individual may not exceed the applicable copayment amount for the product under the prescription drug plan or MA–PD plan in which the individual is enrolled.
(E)Subject to paragraph (6) of this subsection and subsection (c), the substitution for the cost-sharing imposed under section 1395w–102(b)(4)(A) of this title of a copayment or coinsurance not to exceed the copayment or coinsurance amount specified under section 1395w–102(b)(4)(A)(i)(I)(aa) of this title for the drug and year involved. For plan year 2023, the amount of the copayment or coinsurance applicable under the preceding sentence to a month’s supply of a covered insulin product (as defined in section 1395w–102(b)(9)(C) of this title) dispensed to the individual may not exceed the applicable copayment amount for the product under the prescription drug plan or MA–PD plan in which the individual is enrolled.
(3)(A)For purposes of this part, subject to subparagraph (F), the term “subsidy eligible individual” means a part D eligible individual who—
(i)is enrolled in a prescription drug plan or MA–PD plan;
(ii)has income below 150 percent of the poverty line applicable to a family of the size involved; and
(iii)meets the resources requirement described in subparagraph (D) or (E).
(B)(i)The determination of whether a part D eligible individual residing in a State is a subsidy eligible individual and whether the individual is described in paragraph (1) shall be determined under the State plan under subchapter XIX for the State under section 1396u–5(a) of this title or by the Commissioner of Social Security. There are authorized to be appropriated to the Social Security Administration such sums as may be necessary for the determination of eligibility under this subparagraph.
(ii)Determinations under this subparagraph shall be effective beginning with the month in which the individual applies for a determination that the individual is a subsidy eligible individual and shall remain in effect for a period specified by the Secretary, but not to exceed 1 year.
(iii)Redeterminations and appeals, with respect to eligibility determinations under clause (i) made under a State plan under subchapter XIX, shall be made in accordance with the frequency of, and manner in which, redeterminations and appeals of eligibility are made under such plan for purposes of medical assistance under such subchapter.
(iv)With respect to eligibility determinations under clause (i) made by the Commissioner of Social Security—
(I)redeterminations shall be made at such time or times as may be provided by the Commissioner;
(II)the Commissioner shall establish procedures for appeals of such determinations that are similar to the procedures described in the third sentence of section 1383(c)(1)(A) of this title; and
(III)judicial review of the final decision of the Commissioner made after a hearing shall be available to the same extent, and with the same limitations, as provided in subsections (g) and (h) of section 405 of this title.
(v)Subject to subparagraph (F), the Secretary—
(I)shall provide that part D eligible individuals who are full-benefit dual eligible individuals (as defined in section 1396u–5(c)(6) of this title) or who are recipients of supplemental security income benefits under subchapter XVI shall be treated as subsidy eligible individuals described in paragraph (1); and
(II)may provide that part D eligible individuals not described in subclause (I) who are determined for purposes of the State plan under subchapter XIX to be eligible for medical assistance under clause (i), (iii), or (iv) of section 1396a(a)(10)(E) of this title are treated as being determined to be subsidy eligible individuals described in paragraph (1).
(vi)Notwithstanding the preceding provisions of this subparagraph, in the case of an individual whose spouse dies during the effective period for a determination or redetermination that has been made under this subparagraph, such effective period shall be extended through the date that is 1 year after the date on which the determination or redetermination would (but for the application of this clause) otherwise cease to be effective.
(C)For purposes of applying this section—
(i)in the case of a part D eligible individual who is not treated as a subsidy eligible individual under subparagraph (B)(v), income shall be determined in the manner described in section 1396d(p)(1)(B) of this title, without regard to the application of section 1396a(r)(2) of this title and except that support and maintenance furnished in kind shall not be counted as income; and
(ii)the term “poverty line” has the meaning given such term in section 9902(2) of this title, including any revision required by such section.
(D)The resources requirement of this subparagraph is that an individual’s resources (as determined under section 1382b of this title for purposes of the supplemental security income program subject to the life insurance policy exclusion provided under subparagraph (G)) do not exceed—
(i)for 2006 three times the maximum amount of resources that an individual may have and obtain benefits under that program; and
(ii)for a subsequent year the resource limitation established under this clause for the previous year increased by the annual percentage increase in the consumer price index (all items; U.S. city average) as of September of such previous year.
(E)(i)The resources requirement of this subparagraph is that an individual’s resources (as determined under section 1382b of this title for purposes of the supplemental security income program subject to the life insurance policy exclusion provided under subparagraph (G)) do not exceed—
(I)for 2006, $10,000 (or $20,000 in the case of the combined value of the individual’s assets or resources and the assets or resources of the individual’s spouse); and
(II)for a subsequent year the dollar amounts specified in this subclause (or subclause (I)) for the previous year increased by the annual percentage increase in the consumer price index (all items; U.S. city average) as of September of such previous year.
(ii)The Secretary, jointly with the Commissioner of Social Security, shall—
(I)develop a model, simplified application form and process consistent with clause (iii) for the determination and verification of a part D eligible individual’s assets or resources under this subparagraph; and
(II)provide such form to States.
(iii)Under such process—
(I)the application form shall consist of an attestation under penalty of perjury regarding the level of assets or resources (or combined assets and resources in the case of a married part D eligible individual) and valuations of general classes of assets or resources;
(II)such form shall be accompanied by copies of recent statements (if any) from financial institutions in support of the application; and
(III)matters attested to in the application shall be subject to appropriate methods of verification.
(iv)The Secretary may permit a State in making eligibility determinations for premium and cost-sharing subsidies under this section to use the same asset or resource methodologies that are used with respect to eligibility for medical assistance for medicare cost-sharing described in section 1396d(p) of this title so long as the Secretary determines that the use of such methodologies will not result in any significant differences in the number of individuals determined to be subsidy eligible individuals.
(F)In the case of a part D eligible individual who is not a resident of the 50 States or the District of Columbia, the individual is not eligible to be a subsidy eligible individual under this section but may be eligible for financial assistance with prescription drug expenses under section 1396u–5(e) of this title.
(G)In determining the resources of an individual (and the eligible spouse of the individual, if any) under section 1382b of this title for purposes of subparagraphs (D) and (E) no part of the value of any life insurance policy shall be taken into account.
(4)(A)The dollar amounts applied under paragraph (1)(D)(ii)—
(i)for 2007 shall be the dollar amounts specified in such paragraph increased by the annual percentage increase in the consumer price index (all items; U.S. city average) as of September of such previous year; or
(ii)for a subsequent year (before 2028) shall be the dollar amounts specified in this clause (or clause (i)) for the previous year increased by the annual percentage increase in the consumer price index (all items; U.S. city average) as of September of such previous year.
(B)The dollar amount applied under paragraph (2)(B)—
(i)for 2007 shall be the dollar amount specified in such paragraph increased by the annual percentage increase described in section 1395w–102(b)(6) of this title for 2007; or
(ii)for a subsequent year shall be the dollar amount specified in this clause (or clause (i)) for the previous year increased by the annual percentage increase described in section 1395w–102(b)(6) of this title for the year involved.
(5)The Secretary shall, under procedures established by the Secretary, permit a prescription drug plan or an MA–PD plan to waive the monthly beneficiary premium for a subsidy eligible individual if the amount of such premium is de minimis. If such premium is waived under the plan, the Secretary shall not reassign subsidy eligible individuals enrolled in the plan to other plans based on the fact that the monthly beneficiary premium under the plan was greater than the low-income benchmark premium amount.
(6)For plan years beginning on or after January 1, 2023, with respect to an adult vaccine recommended by the Advisory Committee on Immunization Practices (as defined in section 1395w–102(b)(8)(B) of this title)—
(A)the deductible under section 1395w–102(b)(1) of this title shall not apply; and
(B)there shall be no cost-sharing under this section with respect to such vaccine.
(b)(1)The premium subsidy amount described in this subsection for a subsidy eligible individual residing in a PDP region and enrolled in a prescription drug plan or MA–PD plan is the low-income benchmark premium amount (as defined in paragraph (2)) for the PDP region in which the individual resides or, if greater, the amount specified in paragraph (3).
(2)(A)For purposes of this subsection, the term “low-income benchmark premium amount” means, with respect to a PDP region in which—
(i)all prescription drug plans are offered by the same PDP sponsor, the weighted average of the amounts described in subparagraph (B)(i) for such plans; or
(ii)there are prescription drug plans offered by more than one PDP sponsor, the weighted average of amounts described in subparagraph (B) for prescription drug plans and MA–PD plans described in section 1395w–21(a)(2)(A)(i) of this title offered in such region.
(B)The premium amounts described in this subparagraph are, in the case of—
(i)a prescription drug plan that is a basic prescription drug plan, the monthly beneficiary premium for such plan;
(ii)a prescription drug plan that provides alternative prescription drug coverage the actuarial value of which is greater than that of standard prescription drug coverage, the portion of the monthly beneficiary premium that is attributable to basic prescription drug coverage; and
(iii)an MA–PD plan, the portion of the MA monthly prescription drug beneficiary premium that is attributable to basic prescription drug benefits (described in section 1395w–22(a)(6)(B)(ii) 11 So in original. section 1395w–22(a)(6) of this title does not contain a subpar. (B). of this title) and determined before the application of the monthly rebate computed under section 1395w–24(b)(1)(C)(i) of this title for that plan and year involved and, in the case of a qualifying plan, before the application of the increase under section 1395w–23(o) of this title for that plan and year involved.
(3)In no case shall the premium subsidy amount under this subsection for a PDP region be less than the lowest monthly beneficiary premium for a prescription drug plan that offers basic prescription drug coverage in the region.
(c)(1)The Secretary shall provide a process whereby, in the case of a part D eligible individual who is determined to be a subsidy eligible individual and who is enrolled in a prescription drug plan or is enrolled in an MA–PD plan—
(A)the Secretary provides for a notification of the PDP sponsor or the MA organization offering the plan involved that the individual is eligible for a subsidy and the amount of the subsidy under subsection (a);
(B)the sponsor or organization involved reduces the premiums or cost-sharing otherwise imposed by the amount of the applicable subsidy and submits to the Secretary information on the amount of such reduction;
(C)the Secretary periodically and on a timely basis reimburses the sponsor or organization for the amount of such reductions; and
(D)the Secretary ensures the confidentiality of individually identifiable information.
(2)The reimbursement under this section with respect to cost-sharing subsidies may be computed on a capitated basis, taking into account the actuarial value of the subsidies and with appropriate adjustments to reflect differences in the risks actually involved.
(d)Beginning not later than January 1, 2011, the Secretary shall, in the case of a subsidy eligible individual who is enrolled in one prescription drug plan and is subsequently reassigned by the Secretary to a new prescription drug plan, provide the individual, within 30 days of such reassignment, with—
(1)information on formulary differences between the individual’s former plan and the plan to which the individual is reassigned with respect to the individual’s drug regimens; and
(2)a description of the individual’s right to request a coverage determination, exception, or reconsideration under section 1395w–104(g) of this title, bring an appeal under section 1395w–104(h) of this title, or resolve a grievance under section 1395w–104(f) of this title.
(e)(1)Beginning not later than January 1, 2024, the Secretary shall carry out a program to provide transitional coverage for covered part D drugs for LI NET eligible individuals in accordance with this subsection.
(2)For purposes of this subsection, the term “LI NET eligible individual” means a part D eligible individual who—
(A)meets the requirements of clauses (ii) and (iii) of subsection (a)(3)(A); and
(B)has not yet enrolled in a prescription drug plan or an MA–PD plan, or, who has so enrolled, but with respect to whom coverage under such plan has not yet taken effect.
(3)For purposes of this subsection, the term “transitional coverage” means with respect to an LI NET eligible individual—
(A)immediate access to covered part D drugs at the point of sale during the period that begins on the first day of the month such individual is determined to meet the requirements of clauses (ii) and (iii) of subsection (a)(3)(A) and ends on the date that coverage under a prescription drug plan or MA–PD plan takes effect with respect to such individual; and
(B)in the case of an LI NET eligible individual who is a full-benefit dual eligible individual (as defined in section 1396u–5(c)(6) of this title) or a recipient of supplemental security income benefits under subchapter XVI, retroactive coverage (in the form of reimbursement of the amounts that would have been paid under this part had such individual been enrolled in a prescription drug plan or MA–PD plan) of covered part D drugs purchased by such individual during the period that begins on the date that is the later of—
(i)the date that such individual was first eligible for a low-income subsidy under this part; or
(ii)the date that is 36 months prior to the date such individual enrolls in a prescription drug plan or MA–PD plan,
(4)(A)The Secretary shall, as determined appropriate by the Secretary, administer the program under this subsection through a contract with a single program administrator.
(B)The Secretary shall ensure that the transitional coverage provided to LI NET eligible individuals under this subsection—
(i)provides access to all covered part D drugs under an open formulary;
(ii)permits all pharmacies determined by the Secretary to be in good standing to process claims under the program;
(iii)is consistent with such requirements as the Secretary considers necessary to improve patient safety and ensure appropriate dispensing of medication; and
(iv)meets such other requirements as the Secretary may establish.
(5)(A)The following provisions shall not apply with respect to the program under this subsection:
(i)Paragraphs (1) and (3)(B) of section 1395w–104(a) of this title (relating to dissemination of general information; availability of information on changes in formulary through the internet).
(ii)Subparagraphs (A) and (B) of section 1395w–104(b)(3) of this title (relating to requirements on development and application of formularies; formulary development).
(iii)Paragraphs (1)(C) and (2) of section 1395w–104(c) of this title (relating to medication therapy management program).
(B)The Secretary may waive such other requirements of subchapter XI and this subchapter as may be necessary to carry out the purposes of the program established under this subsection.
(6)The authority vested in the Secretary by this subsection may be performed without regard to such provisions of law or regulations relating to the making, performance, amendment, or modification of contracts of the United States as the Secretary may determine to be inconsistent with the furtherance of the purpose of this subchapter.
(f)For special provisions under the medicaid program relating to medicare prescription drug benefits, see section 1396u–5 of this title.
Legislative History
Notes & Related Subsidiaries
Editorial Notes
Amendments
2026—Subsec. (a)(1)(D)(ii). Pub. L. 119–75, § 6219(1), substituted “that does not exceed—”, subcls. (I) and (II), and concluding provisions for “that does not exceed $1 for a generic drug or a preferred drug that is a multiple source drug (as defined in section 1396r–8(k)(7)(A)(i) of this title) and $3 for any other drug, or, if less, the copayment amount applicable to an individual under clause (iii).” Subsec. (a)(4)(A)(ii). Pub. L. 119–75, § 6219(2), inserted “(before 2028)” after “a subsequent year”. 2022—Subsec. (a). Pub. L. 117–169, § 11404(1), substituted “certain individuals” for “individuals with income up to 150 percent of poverty line” in heading. Subsec. (a)(1). Pub. L. 117–169, § 11404(2), substituted “Individuals with certain low incomes” for “Individuals with income below 135 percent of poverty line” in heading and, in introductory provisions, inserted “(or, with respect to a plan year beginning on or after
January 1, 2024, 150 percent)” after “135 percent” and “(or, with respect to a plan year beginning on or after
January 1, 2024, paragraph (3)(E))” after “the resources requirement described in paragraph (3)(D)”. Subsec. (a)(1)(C). Pub. L. 117–169, § 11201(e)(3)(A)(i), substituted “For a year preceding 2025, the continuation” for “The continuation”. Subsec. (a)(1)(D)(ii). Pub. L. 117–169, § 11401(b)(1), substituted “Subject to paragraph (6), in the case” for “In the case”. Subsec. (a)(1)(D)(iii). Pub. L. 117–169, § 11406(b)(1)(A), inserted at end “For plan year 2023 and subsequent plan years, the copayment amount applicable under the preceding sentence to a month’s supply of a covered insulin product (as defined in section 1395w–102(b)(9)(C) of this title) dispensed to the individual may not exceed the applicable copayment amount for the product under the prescription drug plan or MA–PD plan in which the individual is enrolled.” Pub. L. 117–169, § 11401(b)(1), substituted “Subject to paragraph (6), in the case” for “In the case”. Pub. L. 117–169, § 11201(e)(3)(A)(ii), substituted “1395w–102(b)(4)(A)(i)(I)(aa)” for “1395w–102(b)(4)(A)(i)(I)”. Subsec. (a)(1)(E). Pub. L. 117–169, § 11406(b)(1)(B), inserted before period at end “or under section 1395w–102(b)(9) of this title in the case of a covered insulin product (as defined in subparagraph (C) of such section)”. Pub. L. 117–169, § 11201(e)(3)(A)(iii), substituted “For a year preceding 2024, the elimination” for “The elimination”. Subsec. (a)(2). Pub. L. 117–169, § 11404(3), substituted “Other low-income individuals” for “Other individuals with income below 150 percent of poverty line” in heading and “With respect to a plan year beginning before
January 1, 2024, in the case of a subsidy” for “In the case of a subsidy” in introductory provisions. Subsec. (a)(2)(B). Pub. L. 117–169, § 11406(b)(2)(A), substituted “paragraphs (8) and (9) of section 1395w–102(b)” for “section 1395w–102(b)(8)”. Pub. L. 117–169, § 11401(b)(2)(A), substituted “Subject to section 1395w–102(b)(8) of this title, a reduction” for “A reduction”. Subsec. (a)(2)(D). Pub. L. 117–169, § 11406(b)(2)(B), inserted at end “For plan year 2023, the amount of the coinsurance applicable under the preceding sentence to a month’s supply of a covered insulin product (as defined in section 1395w–102(b)(9)(C) of this title) dispensed to the individual may not exceed the applicable copayment amount for the product under the prescription drug plan or MA–PD plan in which the individual is enrolled.” Pub. L. 117–169, § 11401(b)(2)(B), substituted “Subject to paragraph (6), the substitution” for “The substitution”. Subsec. (a)(2)(E). Pub. L. 117–169, § 11406(b)(2)(C), inserted at end “For plan year 2023, the amount of the copayment or coinsurance applicable under the preceding sentence to a month’s supply of a covered insulin product (as defined in section 1395w–102(b)(9)(C) of this title) dispensed to the individual may not exceed the applicable copayment amount for the product under the prescription drug plan or MA–PD plan in which the individual is enrolled.” Pub. L. 117–169, § 11401(b)(2)(C), substituted “paragraph (6) of this subsection and subsection (c)” for “subsection (c)”. Pub. L. 117–169, § 11201(e)(3)(B), substituted “1395w–102(b)(4)(A)(i)(I)(aa)” for “1395w–102(b)(4)(A)(i)(I)”. Subsec. (a)(6). Pub. L. 117–169, § 11401(b)(3), added par. (6). 2020—Subsecs. (e), (f). Pub. L. 116–260 added subsec. (e) and redesignated former subsec. (e) as (f). 2010—Subsec. (a)(1)(D)(i). Pub. L. 111–148, § 3309, inserted “or, effective on a date specified by the Secretary (but in no case earlier than
January 1, 2012), who would be such an institutionalized individual or couple, if the full-benefit dual eligible individual were not receiving services under a home and community-based waiver authorized for a State under section 1315 of this title or subsection (c) or (d) of section 1396n of this title or under a State plan amendment under subsection (i) of such section or services provided through enrollment in a medicaid managed care organization with a contract under section 1396b(m) of this title or under section 1396u–2 of this title” after “1396a(q)(1)(B) of this title)”. Subsec. (a)(3)(B)(vi). Pub. L. 111–148, § 3304(a), added cl. (vi). Subsec. (a)(5). Pub. L. 111–148, § 3303(a), added par. (5). Subsec. (b)(2)(B)(iii). Pub. L. 111–152 substituted “and determined before the application of the monthly rebate computed under section 1395w–24(b)(1)(C)(i) of this title for that plan and year involved and, in the case of a qualifying plan, before the application of the increase under section 1395w–23(o) of this title for that plan and year involved” for “, determined without regard to any reduction in such premium as a result of any beneficiary rebate under section 1395w–24(b)(1)(C) of this title or bonus payment under section 1395w–23(n) of this title”. Pub. L. 111–148, § 3302(a), inserted “, determined without regard to any reduction in such premium as a result of any beneficiary rebate under section 1854(b)(1)(C) or bonus payment under section 1395w–23(n) of this title” before period at end. Subsecs. (d), (e). Pub. L. 111–148, § 3305, added subsec. (d) and redesignated former subsec. (d) as (e). 2008—Subsec. (a)(1)(A). Pub. L. 110–275, § 114(a)(2), substituted “equal to 100 percent of the amount described in subsection (b)(1), but not to exceed the premium amount specified in subsection (b)(2)(B).” for “equal to— “(i) 100 percent of the amount described in subsection (b)(1) of this section, but not to exceed the premium amount specified in subsection (b)(2)(B) of this section; plus “(ii) 80 percent of any late enrollment penalties imposed under section 1395w–113(b) of this title for the first 60 months in which such penalties are imposed for that individual, and 100 percent of any such penalties for any subsequent month.” Subsec. (a)(3)(B)(iv)(III). Pub. L. 110–275, § 117(a), added subcl. (III). Subsec. (a)(3)(C)(i). Pub. L. 110–275, § 116(a)(1), inserted “and except that support and maintenance furnished in kind shall not be counted as income” after “section 1396a(r)(2) of this title”. Subsec. (a)(3)(D), (E)(i). Pub. L. 110–275, § 116(a)(2), (3), inserted “subject to the life insurance policy exclusion provided under subparagraph (G)” after “program” in introductory provisions. Subsec. (a)(3)(G). Pub. L. 110–275, § 116(a)(4), added subpar. (G).
Statutory Notes and Related Subsidiaries
Effective Date
of 2010 Amendment Pub. L. 111–148, title III, § 3302(b), Mar. 23, 2010, 124 Stat. 468, provided that: “The amendment made by subsection (a) [amending this section] shall apply to premiums for months beginning on or after
January 1, 2011.” Amendment by section 3303(a) of Pub. L. 111–148 applicable to premiums for months, and enrollments for plan years, beginning on or after
January 1, 2011, see section 3303(c) of Pub. L. 111–148, set out as a note under section 1395w–101 of this title. Pub. L. 111–148, title III, § 3304(b), Mar. 23, 2010, 124 Stat. 470, provided that: “The amendment made by subsection (a) [amending this section] shall take effect on
January 1, 2011.”
Effective Date
of 2008 AmendmentAmendment by section 114(a)(2) of Pub. L. 110–275 applicable to subsidies for months beginning with Jan. 2009, see section 114(b) of Pub. L. 110–275, set out as a note under section 1395w–113 of this title. Pub. L. 110–275, title I, § 116(b), July 15, 2008, 122 Stat. 2507, provided that: “The
Amendments
made by this section [amending this section] shall take effect with respect to applications filed on or after
January 1, 2010.” Pub. L. 110–275, title I, § 117(b),
July 15, 2008, 122 Stat. 2507, provided that: “The
Amendments
made by subsection (a) [amending this section] shall take effect as if included in the enactment of section 101 of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 [Pub. L. 108–173].”
Construction
of 2022 AmendmentNothing in amendment by section 11401(b) of Pub. L. 117–169 to be construed as limiting coverage under this part for vaccines that are not recommended by the Advisory Committee on Immunization Practices, see section 11401(d) of Pub. L. 117–169, set out as a note under section 1395w–102 of this title. GAO Study Regarding Impact of Assets Test for Subsidy Eligible Individuals Pub. L. 108–173, title I, § 107(e), Dec. 8, 2003, 117 Stat. 2171, provided that: “(1) Study.—The Comptroller General of the United States shall conduct a study to determine the extent to which drug utilization and access to covered part D drugs under part D of title XVIII of the Social Security Act [42 U.S.C. 1395w–101 et seq.] by subsidy eligible individuals differs from such utilization and access for individuals who would qualify as such subsidy eligible individuals but for the application of section 1860D–14(a)(3)(A)(iii) of such Act [42 U.S.C. 1395w–114(a)(3)(A)(iii)]. “(2) Report.—Not later than September 30, 2007, the Comptroller General shall submit a report to Congress on the study conducted under paragraph (1) that includes such recommendations for legislation as the Comptroller General determines are appropriate.”
Reference
Citations & Metadata
Citation
42 U.S.C. § 1395w–114
Title 42 — The Public Health and Welfare
Last Updated
Apr 18, 2026
Release point: 119-83